Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 5/2000

01-11-2000 | Clinical Pharmacology

Clinical Dosage Determination of a New Aromatase Inhibitor, Anastrozole, in Postmenopausal Japanese Women with Advanced Breast Cancer

Authors: Yasuo Nomura, Hiroki Koyama, Yasuo Ohashi, Hiroshi Watanabe

Published in: Clinical Drug Investigation | Issue 5/2000

Login to get access

Abstract

Objective: To determine the recommended clinical dosage in Japan of a new aromatase inhibitor, anastrozole.
Design and Setting: A randomised, nonblinded, dose-comparative clinical pharmacology study was performed in healthy postmenopausal Japanese women, followed by a multicentre, randomised, nonblinded, parallel-group early phase II study in postmenopausal Japanese patients with advanced breast cancer.
Patients and Participants: 24 women were enrolled in the clinical pharmacological study and 73 in the efficacy study, of whom 70 were available for analysis.
Methods: In the initial phase of the clinical pharmacology study, 12 women received a single oral dose of anastrozole 0.5 or 1mg. Then, a further 12 women received anastrozole 0.5 or 1 mg/day for 14 days to study the tolerability and the pharmacokinetic and pharmacodynamic profiles of the drug. In the efficacy study, the patients with advanced breast cancer received anastrozole 0.5 or 1 mg/day for 12 weeks or more and tumour response was determined at 4-week intervals during treatment.
Results: Plasma concentrations of anastrozole reached steady state by days 8 to 10 of administration. The mean trough concentrations at steady state for anastrozole 0.5 and 1 mg/day were 15.8 and 35.9 μg/L, respectively. Anastrozole at both 0.5 and 1 mg/day significantly reduced plasma estradiol concentrations in comparison with baseline values. Daily exposure to estradiol at day 14 (geometric mean plasma estradiol concentrations) was significantly lower in participants receiving anastrozole 1 mg/day than in those receiving 0.5 mg/day (4.05 vs 5.95 pmol/L, p = 0.016). In the efficacy study, objective response rates were 27.8% (10 of 36) and 38.2% (13 of 34) in the 0.5 and 1 mg/day treatment groups, respectively. Complete response was observed in two patients in the 1 mg/day treatment group compared with none in the 0.5 mg/day treatment group.
Conclusions: The superiority of the 1 mg/day dosage in the clinical pharmacology study was also demonstrated in the efficacy study. Therefore, we recommend that the clinical dosage of anastrozole in Japan should be 1mg once daily.
Literature
1.
Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30: 103–11PubMedCrossRef
2.
Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of Arimidex (anastrozole; ZD1033): a potent, selective aromatase inhibitor. J Steroid Biochem Molec Biol 1996; 58(4): 439–45PubMedCrossRef
3.
Plourde PV, Dyroff M, Dowsett M, et al. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem MolecBiol 1995; 53: 175–9CrossRef
4.
Yates RA, Dowsett M, Fisher GV, et al. ARIMIDEX (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73: 543–8PubMedCrossRef
5.
Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286–91PubMedCrossRef
6.
Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A(3): 404–12PubMedCrossRef
7.
Buzdar AU, Jones SE, Vogel CL, et al. Aphase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997; 79: 730–9PubMedCrossRef
8.
Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer 1998; 83: 1142–52PubMedCrossRef
9.
Koyama H, Abe R, Tominaga T, et al. Clinical phase I trial for anastrozole: a new fourth generation aromatase inhibitor. Jpn J Breast Cancer. In press
10.
Yakuhatsu 874. Tokyo: Ministry of Health and Welfare, 1989
11.
Pharmaceutical Affairs Bureau. Guidelines for clinical evaluation methods of antimalignant tumor drugs. PAB notification no. 9. Tokyo: Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, 1991 Feb 4
12.
Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 12th ed. Tokyo: Kanehara Press, 1996
13.
Dowsett M, Goss PE, Powles TJ, et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987; 47: 1957–61PubMed
14.
Japan Society for Cancer Therapy. Criteria for the evaluation of direct effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993, 28: 101–30
15.
Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69(12): 1375–81PubMed
16.
Anon. Clinical trial report: dose proportionality study of ZENECA ZD1033 (ARIMIDEX™) in postmenopausal women. 1994 Aug 25. AstraZeneca, UK (Data on file)
Metadata
Title
Clinical Dosage Determination of a New Aromatase Inhibitor, Anastrozole, in Postmenopausal Japanese Women with Advanced Breast Cancer
Authors
Yasuo Nomura
Hiroki Koyama
Yasuo Ohashi
Hiroshi Watanabe
Publication date
01-11-2000
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 5/2000
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200020050-00007

Other articles of this Issue 5/2000

Clinical Drug Investigation 5/2000 Go to the issue

Clinical Use

Survival Meta-Analysis of Individual Patient Data and Survival Meta-Analysis of Published (Aggregate) Data

Clinical Use

Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease

Drug Interactions

Dose-Sparing Effect of Midazolam on Etomidate when Inducing Hypnosis

Clinical Use

Zanamivir for the Treatment of Clinically Diagnosed Influenza in Clinical Practice

Correspondence

Comparison between an Apparently Obsolete Protocol and an Updated Regimen in the Salvage Treatment of Advanced Colorectal Cancer

Clinical Use

Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients